Ads by Google

Arthritis Pain Treatment

Gout Sufferers Now Have Uloric for Treatment

2009-02-15 19:46

Gout is a painful joint disease affecting about five million people in the United States. Gout is a form of arthritis that is caused by a build-up of uric acid in the blood.

On Friday, the Food and Drug Administration approved Uloric (febuxostat) giving gout sufferers a new drug to treat their disease. It is the first new treatment for gout in over 40 years. The drug is produced by Takeda Pharmaceuticals North America, Inc.

Uloric works by blocking the enzyme xanthine oxidase and therefore reducing levels of blood uric acid. It is a once-daily drug.

New Guidelines for Treatment of Knee Osteoarthritis

2009-02-04 11:44

The American Academy of Orthopaedic Surgeons (AAOS) released its recommendations in December 2008 for "best" practice guidelines. In looking at the commonly used treatments for osteoarthritis (OA), they underscored that many lack support from scientific evidence.

The AAOS guideline targets treatment for patients with OA of the knee whose disease has not progressed to the point of needing joint replacement surgery. It offers 22 treatment recommendations. The guideline is aimed at primary care physicians as well as orthopedic surgeons.

Study Shows Rheumatoid Arthritis Responding To Gene Therapy

2009-02-02 09:26

A study that delivers the first clinical evidence that gene therapy can reduce the symptoms of patients with rheumatoid arthritis appeared in the February issue of Human Gene Therapy. The authors of the study, which was carried out in 1997 and 1998 under the direction of Dr. Peter Wehling, Düsseldorf, Germany, describe the findings of a study involving two patients with severe rheumatoid arthritis.

No Proven Role For Diet In Treating Rheumatoid Arthritis

2009-01-29 10:30

A new review finds no definitive connection between diet and rheumatoid arthritis (RA), a disease in which the body’s immune system attacks the lining of the joints.

As an individual’s rheumatoid arthritis progresses, his or her joints can become swollen and stiff, reducing mobility. While treatments are available to relieve some of these symptoms, no cure exists.

Novel Drugs May Be Hope For Rheumatoid Arthritis Treatment

2009-01-13 17:04

Methotrexate (MTX), a folate antagonist that blocks folic acid activity, is the most widely used disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. It enters the cell via several pathways, one of which involves folate receptor β (FRβ), which is highly specific for cells present in the joints of patients with rheumatoid arthritis (RA). During the last two decades, a second generation of folate antagonists has been designed to address some of the limitations of MTX, which include adverse side effects and resistance.

New Clinical Practice Guideline For Knee Osteoarthritis Issued

2008-12-12 07:26

The American Academy of Orthopaedic Surgeons (AAOS) has approved and released an evidence-based clinical practice guideline on "Treatment of Osteoarthritis of the Knee". These guidelines were explicitly developed to include only treatments which are less invasive than knee replacement surgery. While a wide range of treatment options are available, they should always be tailored to individual patients after discussions with their physicians.

The Guidelines and Evidence Report recommends:

CEL-SCI's Rheumatoid Arthritis Vaccine Benefits Last Long

2008-11-15 00:23

CEL-SCI Corporation presented new rheumatoid arthritis data at the 6th annual GTCbio Vaccine Conference in Vienna, Va. The data, presented by Dr. Daniel Zimmerman, Senior Vice President of Research, Cellular Immunology of CEL-SCI, indicate that CEL-SCI's rheumatoid arthritis treatment vaccine CEL-2000 prevents or retards the permanent tissue damage caused by rheumatoid arthritis. The long term results obtained with CEL-2000 vaccine, for the rheumatoid arthritis, were in line with those seen with Enbrel, a leading treatment for people with rheumatoid arthritis.

Antiangiogenic Role Of 2ME2 Demonstrated In Rheumatoid Arthritis Models

2008-11-03 23:41

EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publication of preclinical results for 2ME2 (Panzem or 2-methoxyestradiol) in rheumatoid arthritis (RA). The results of the study, conducted by EntreMed collaborator, Dr. Ernest Brahn, Professor of Medicine, Rheumatology Program Director, David Geffen School of Medicine at UCLA, were published in the November 2008 issue of the Journal of Rheumatology (Brahn E, Banquerigo ML, Lee JK, Park EJ, Fogler WE, and Plum SM.

ACTEMRA Inhibited Progression Of Joint Damage In RA Patients Demonstrated

2008-10-29 07:40

One-year data from a two-year Phase III study demonstrated that ACTEMRA (tocilizumab) significantly inhibited the progression of structural joint damage in patients with rheumatoid arthritis (RA). Late-breaking results from the LITHE study will be featured as an oral presentation during the American College of Rheumatology (ACR) Annual Scientific Meeting (October 24-28) in San Francisco. Fourteen additional abstracts, which evaluate ACTEMRA, a novel interleukin-6 (IL-6) receptor inhibitor, in patients with moderately to severely active RA, will also be presented during the meeting.

ACTEMRA Significantly Reduced Signs, Symptoms Of Rheumatoid Arthritis

2008-10-28 00:49

Data from two Phase III studies showed that patients who suffer from the debilitating and painful effects of rheumatoid arthritis (RA) achieved significant improvements in signs and symptoms when treated with ACTEMRA (tocilizumab) alone or in combination with methotrexate compared with methotrexate alone.